Clinical controlled study on plaque and gingivitis reduction under long-term use of low-dose chlorhexidine solutions in a population exhibiting good oral hygiene.
The aim of this randomized, parallel-group, placebo-controlled, blind clinical study was to examine the dental plaque and the gingivitis inhibitory effects of two low-dose 0.06% chlorhexidine (CHX) preparations in comparison to a commercially available 0.1% CHX solution, an amine fluoride/stannous fluoride (ASF) solution and a water control as an adjunct to the daily mechanical oral-hygiene measures. After prophylaxis, 81 medical students performed their tooth cleaning and were asked to rinse for 30 s, according to the instructions given by the manufacturers with the assigned amount of the following solutions: once daily 10 ml ASF 250 ppm or twice daily each 10 ml CHX 0.06% with fluoride, 10 ml CHX 0.06% without fluoride, 15 ml CHX 0.1% or 100 ml tap water. The plaque index (PlI), the gingival index (GI) and the discoloration index (DI) were taken at day -14 and months (M) 0, 1, 2, 3 and 6. In this study group with good oral hygiene, all test products led to a reduction of the PlI scores when used as supplements to the usual mechanical hygiene measures. At M3 subjects using both the 0.1% as well as the 0.06% CHX showed significantly less plaque accumulation than those using ASF. In the GI a significant difference between the control and 0.1 % CHX was found at M3 and at M6. If a further decrease in the GI is wanted, a minimum concentration of 0.1% CHX for long-term use in association with habitual cleaning is needed, which, however, should be limited to special patients. If maintaining clinical health is the goal, the other solutions are a good alternative to 0.1% CHX because they exhibit less staining.
Hoffmann
T
T
Department of Periodontology, Dental School TU Dresden, Germany. th.hoffm@rcs.urz.tu-dresden.de
Bruhn
G
G
Richter
S
S
Netuschil
L
L
Brecx
M
M
D000293:Adolescent; D000328:Adult; D000588:Amines / Q000008:administration & dosage / Q000627:therapeutic use; D000704:Analysis of Variance; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use*; D002327:Cariostatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002710:Chlorhexidine / Q000008:administration & dosage / Q000627:therapeutic use*; D003773:Dental Plaque / Q000517:prevention & control*; D003774:Dental Plaque Index; D004338:Drug Combinations; D005260:Female; D005459:Fluorides / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D005891:Gingivitis / Q000517:prevention & control*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D009067:Mouthwashes / Q000627:therapeutic use*; D009910:Oral Hygiene; D010512:Periodontal Index; D010919:Placebos; D016037:Single-Blind Method; D013223:Statistics as Topic; D018709:Statistics, Nonparametric; D014002:Tin Fluorides / Q000008:administration & dosage / Q000627:therapeutic use; D014075:Tooth Discoloration / Q000139:chemically induced / Q000145:classification
D000588:Amines; D000891:Anti-Infective Agents, Local; D002327:Cariostatic Agents; D004338:Drug Combinations; D009067:Mouthwashes; D010919:Placebos; D014002:Tin Fluorides; C059813:Meridol; D005459:Fluorides; D002710:Chlorhexidine